drugset
drugset / Trial / NCT06104683

A Study of Pirtobrutinib (LY3527727 [LOXO-305]) Versus Placebo in Participants With Relapsing Multiple Sclerosis

NCT06104683 ↗

Phase 2 Withdrawn Loxo Oncology, Inc. Eli Lilly and Company · collab
RandomizedParallel-groupDouble-blindTreatment

Summary

The main purpose of this study is to assess efficacy and safety of pirtobrutinib in participants with relapsing multiple sclerosis.

Timeline

Start
2024-05-01
Primary completion
2026-01-16
Completion
2026-02-13

Outcome

Outcome not reported

Stopped (Business): “Sponsor Decision: The trial has been withdrawn with no plans to continue development.”

Drugs

EvaluationDrugModalityDoseRoute
Subject Pirtobrutinib Small molecule — Oral

Indications

multiple sclerosis